Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.
Nutr Rev. 2020 Oct 1;78(10):827-840. doi: 10.1093/nutrit/nuz098.
Fish oil and omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have anti-inflammatory properties, but their effect on psoriasis and its comorbidities remains inconclusive.
The aim of this quantitative systematic review was to evaluate the efficacy and safety of fish oil and its components in the treatment of psoriasis and its comorbidities.
PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang databases were searched from inception to March 30, 2019.
Randomized controlled trials were eligible for inclusion if they measured the effect of fish oil and its components in the treatment of patients with psoriasis.
Eighteen randomized controlled trials involving 927 study participants were included.
Monotherapy with fish oil or ω-3 PUFAs had no effect on the Psoriasis Area and Severity Index (PASI) score (P = 0.47), lesion area (P = 0.34), or pruritus (P = 0.62). Fish oil or ω-3 PUFAs combined with conventional treatments, however, resulted in a decreased PASI score (mean difference [MD], -3.92; 95%CI, -6.15 to -1.69; P = 0.0006) and lesion area (MD, -30.00; 95%CI, -33.82 to -26.18; P < 0.0001). Safety evaluation suggested no between-group differences. Fish oil and its components reduced certain risk factors for obesity, cardiovascular disease, and metabolic disease in patients with psoriasis and also regulated several inflammatory mediators.
Overall, when combined with conventional treatments, fish oil and its components may have beneficial effects on psoriasis and its comorbidities, including obesity, cardiovascular disease, and metabolic disease.
PROSPERO registration number CRD42019128631.
鱼油和欧米伽-3 多不饱和脂肪酸（ω-3PUFAs）具有抗炎特性，但它们对银屑病及其合并症的影响仍不确定。
本定量系统评价旨在评估鱼油及其成分治疗银屑病及其合并症的疗效和安全性。
从建库到 2019 年 3 月 30 日，检索了 PubMed、Embase、Cochrane 中央对照试验注册库、中国知网、中国科技期刊数据库和万方数据库。
如果测量鱼油及其成分治疗银屑病患者的效果，则纳入随机对照试验。
共纳入 18 项随机对照试验，涉及 927 名研究参与者。
鱼油或 ω-3PUFAs 单药治疗对银屑病面积和严重程度指数（PASI）评分（P = 0.47）、病变面积（P = 0.34）或瘙痒（P = 0.62）均无影响。然而，鱼油或 ω-3PUFAs 与常规治疗联合使用可使 PASI 评分（平均差值[MD]，-3.92；95%置信区间[CI]，-6.15 至-1.69；P = 0.0006）和病变面积（MD，-30.00；95%CI，-33.82 至-26.18；P < 0.0001）降低。安全性评估表明两组间无差异。鱼油及其成分可降低银屑病患者肥胖、心血管疾病和代谢性疾病的某些危险因素，并调节几种炎症介质。
总体而言，鱼油及其成分与常规治疗联合使用可能对银屑病及其合并症（包括肥胖、心血管疾病和代谢性疾病）具有有益作用。
PROSPERO 注册号 CRD42019128631。
